Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer

12 Feb 2016

Abstract excerpt

BACKGROUND: While localized prostate cancer (PCa) can be effectively cured, metastatic disease inevitably progresses to a lethal state called castration-resistant prostate cancer (CRPC). Emerging evidence suggests that aberrant epigenetic repression by the polycomb group (PcG) complexes fuels PCa progression, providing novel therapeutic opportunities. RESULTS: In the search for potential epigenetic drivers of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Epigenetics and DNA Methylation
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26877821
DOI: 10.1186/s13148-016-0182-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancerPMID 26877821Read ↗

A Potent, Selective CBX2 Chromodomain Ligand and Its Cellular Activity During Prostate Cancer Neuroendocrine DifferentiationSemantic proximity Read ↗

Polycomb-mediated silencing in neuroendocrine prostate cancerSemantic proximity Read ↗

The predictive significance of chromobox family members in prostate cancer in humansSemantic proximity Read ↗

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancerSemantic proximity Read ↗

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancerSemantic proximity Read ↗

CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathwaySemantic proximity Read ↗

Essential Role for Activation of the Polycomb Group (PcG) Protein Chromatin Silencing Pathway in Metastatic Prostate CancerSemantic proximity Read ↗

Targeting the p300/CBP Axis in Lethal Prostate CancerSemantic proximity Read ↗

Polycomb Paralog Chromodomain Inhibitors Active Against Both CBX6 and CBX8Semantic proximity Read ↗

A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer OutcomeSemantic proximity Read ↗

Integrated bioinformatics investigation and experimental validation reveals the clinical and biological significance of chromobox family in breast cancerSemantic proximity Read ↗

Common Structural and Epigenetic Changes in the Genome of Castration-Resistant Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.